MAP will send a trained nurse to administer Sandostatin® LAR Depot injections for eligible patients.
About Sandostatin® LAR Depot
What is Sandostatin® LAR Depot (octreotide acetate for injectable suspension)?
Sandostatin® LAR Depot (octreotide acetate for injectable suspension) is similar to somatostatin, a hormone that occurs naturally in the body. Both work to reduce excess hormone secretions that alter various metabolic activities that are important for your body. Sandostatin® LAR Depot, however, remains active in the body much longer than somatostatin. It is formulated as a suspension in microspheres that slowly dissolve over the course of 4 weeks, so it can be administered every 4 weeks as an intragluteal injection (an injection into the gluteal muscle, a large muscle in the buttock).
What is the difference between Sandostatin® LAR Depot (octreotide acetate for injectable suspension) and immediate-release Sandostatin® (octreotide acetate) Injection?
Sandostatin® LAR Depot is a reformulation of immediate-release Sandostatin® Injection, the most prescribed, most studied medical therapy for acromegaly. The active ingredient (octreotide acetate) is the same in both formulations. However, the reformulation allows patients to receive an injection in their gluteal muscle every 4 weeks, given by a health care provider, instead of daily injections.
Sandostatin® LAR Depot is indicated in patients in whom initial treatment with Sandostatin® Injection has been shown to be effective and tolerated.